Literature DB >> 583039

Comparative bioavailability of two commercial preparations of carbamazepine tablets.

M Anttila, P Kahela, M Panelius, T Yrjänä, R Tikkanen, R Aaltonen.   

Abstract

A comparative bioavailability study was performed using two commercially available types of carbamazepine tablets, by statistical analysis of serum levels and other bioavailability parameters. After single oral dose the extent of absorption from the two preparations was similar, although a statistically significant difference in absorption rates was observed. In a multiple-dose study no significant difference in serum carbamazepine levels was found, so the tablets could be considered as bioequivalent drug products.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 583039     DOI: 10.1007/bf00561742

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses.

Authors:  A P Géradin; F V Abadie; J A Campestrini; W Theobald
Journal:  J Pharmacokinet Biopharm       Date:  1976-12

2.  Serum concentration of carbamazepine: comparison of Herrmann's spectrophotometric method and a new GLC method for the determination of carbamazepine.

Authors:  S Pynnönen; M Sillanpää; H Frey; E Iisalo
Journal:  Epilepsia       Date:  1976-03       Impact factor: 5.864

3.  Pharmacokinetics of carbamazepine in normal man.

Authors:  R H Levy; W H Pitlick; A S Troupin; J R Green; J M Neal
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

4.  Distribution and elimination kinetics of carbamazepine in man.

Authors:  M D Rawlins; P Collste; L Bertilsson; L Palmér
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

5.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

6.  Bioavailability of two carbamazepine preparations during chronic administration to epileptic patients.

Authors:  P L Morselli; F Monaco; M Gerna; M Recchia; A Riccio
Journal:  Epilepsia       Date:  1975-12       Impact factor: 5.864

  6 in total
  4 in total

1.  Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals.

Authors:  V W Steinijans; E Diletti
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets.

Authors:  Laszlo Tothfalusi; Szilvia Speidl; Laszlo Endrenyi
Journal:  Br J Clin Pharmacol       Date:  2007-08-15       Impact factor: 4.335

3.  Impact of generic substitution of anticonvulsants on the treatment of epilepsy.

Authors:  A Richens
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

4.  Investigating Oral Absorption of Carbamazepine in Pediatric Populations.

Authors:  Philip Kohlmann; Cordula Stillhart; Martin Kuentz; Neil Parrott
Journal:  AAPS J       Date:  2017-10-02       Impact factor: 4.009

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.